



# Share subscriptions based on Nanoform Finland Plc's multiple Stock Option Programs

Company release

**Nanoform Finland Plc**

April 12, 2022

07:00 p.m. Finnish time / 06:00 p.m. Swedish time

## **Share subscriptions based on Nanoform Finland Plc's multiple Stock Option Programs**

**Helsinki, Finland** – Between March 17 and March 31, 2022, a total of 163,500 Nanoform Finland Plc's (the "Company" or "Nanoform") new shares have been subscribed for with the Company's 1/2019, 2/2019, 3/2019, 5/2019 and 1/2020 stock options programs. The entire subscription price for subscriptions made with the stock options of EUR 203,500 will be entered in the Company's reserve for invested unrestricted equity.

The shares subscribed for under the stock options are expected to be registered in the Trade Register on or about April 25, 2022 as of which date the new shares will establish shareholder rights. As a result of registering the new shares, the number of Nanoform shares will increase to 78,280,464 in total. The new shares will be admitted to trading on Nasdaq First North Premier Growth Market Finland and Sweden on or about April 26, 2022.

For further information, please contact:

Peter Hänninen

General Counsel

[peter.hanninen@nanoform.com](mailto:peter.hanninen@nanoform.com)

+358 50 353 040

For investor relations queries, please contact:

Henri von Haartman

Director of Investor Relations

[hvh@nanoform.com](mailto:hvh@nanoform.com)

+46 7686 650 11

[About Nanoform](#)

Nanoform is an innovative nanoparticle medicine enabling company. Nanoform works together with pharma and biotech partners globally to provide hope for patients in developing new and improved

medicines utilizing Nanoform's platform technologies. The Company focuses on reducing clinical attrition and on enhancing drug molecules' performance through its nanoforming technologies and formulation services. Nanoform's capabilities include GMP manufacturing, and its services span the small to large molecule development space with a focus on solving key issues in drug solubility and bioavailability and on enabling novel drug delivery applications. Nanoform's shares are listed on the Premier-segment of Nasdaq First North Growth Market in Helsinki (ticker: NANOFH) and Stockholm (ticker: NANOFS). Certified Adviser: Danske Bank A/S, Finland Branch, +358 40 562 1806. For more information please visit <http://www.nanoform.com>